Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

EANS-Adhoc: Sygnis Pharma AG
SYGNIS secures up to EUR 10 Million through a 3 year Standby Equity Distribution Agreement with Yorkville

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Company Information
19.10.2009
Heidelberg, 19 October 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN 
DE0005043509; Prime Standard), a clinical stage biotech company 
developing innovative CNS treatments, today announced that it has 
entered into a 3 year standby equity distribution agreement (SEDA) 
with YA Global Master SPV LTD (YA Global).
The agreement provides SYGNIS with the option to request YA Global, 
during the next 36 months, to subscribe for newly issued SYGNIS 
shares, from the company´s authorized capital, in tranches of up to 
EUR 500,000 each. The subscription price of the new shares will be 
determined at 95% of the lowest volume-weighted average price of one 
of the five trading days following the date of the relevant draw down
notice.
The total value of this equity facility aggregates to up to EUR 10 
million, provided that the aggregate number of shares issued to YA 
Global shall not exceed 9,9% of SYGNIS´ share capital. YA Global can 
either accumulate these shares or place them in the market. However, 
YA Global is committed not to short sell or enter into any hedging 
transactions related to particular company stock.
### Disclaimer Some statements included in this press release, 
relating neither to proven financial results nor other historical 
data, should be viewed as forward-looking, i.e. not definite. Such 
statements are mainly predictions of future results, trends, plans or
goals. These statements should not be considered to be total 
guarantees since given their very nature they are subject to known 
and unknown risks and imponderability and can be affected by other 
factors as a consequence of which the actual results, plans and goals
of SYGNIS Pharma AG may deviate greatly from the established 
conclusions or implied predictions contained in such statements. 
SYGNIS does not undertake to publicly update or revise these 
statements in the light of new information or future results or for 
any other reason. ###

Further inquiry note:

Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 6221-454 812
Email: franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG